Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    PUMA-NER-1301
Previous Study | Return to List | Next Study

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Puma Biotechnology, Inc.
Information provided by (Responsible Party):
Puma Biotechnology, Inc. Identifier:
First received: March 4, 2013
Last updated: September 26, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2018
  Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)